Aurobindo Pharma Reports Strong Q3FY26 Performance with 8.4% Revenue Growth
Published on: Feb. 16, 2026, 10:24 p.m. | Source: scanx.trade
Aurobindo Pharma reported strong Q3FY26 results with 8.4% YoY revenue growth to Rs. 8,646 crores and EBITDA of Rs. 1,773 crores at 20.5% margin. European business led growth with 27% YoY increase to Rs. 2,703 crores, while US operations remained stable with injectable sales growing 17% YoY. The company's Pen-G facility ramped up production to 10,000 MT annually, benefiting from government's MIP policy on key antibiotics. Management expressed confidence in achieving higher-end EBITDA margins of 20-21% for FY26.
